MarketPR
In focus for clinical oncology watchers Thursday: Whitehawk Therapeutics (Nasdaq: WHWK) posted a second-quarter 2026 net loss of $16.6 million and ended the period with $190.0 million in cash, cash equivalents and short-term investments.
That balance, up from $145.7 million at December 31, 2025, is anticipated to fund operations into the second half of 2028.
The next confirmable date on the tape is the Phase 1 trial initiation for HWK-206, planned for Q3 2026.
The numbers behind the print Research and development expenses came in at $12.9 million for the quarter ended June 30, 2026, against $48.8 million in the year-prior period.
Keep reading